Previous research has shown that ITP patients harboring mutations in genes such as DNMT3A, TET2, ASXL1, BCOR, PIGA, and U2AF1 tend to progress into other clonal hematologic disorders, leading to treatment ineffectiveness [31]. Here, ASXL1 is linked to hematologic disorder.